Concord Biotech Ltd. (CONCORDBIO): Concord Biotech Share Price Rises 6.05% Amid Market Activity

Concord Biotech Share Price rises 6.05% to Rs 1,413.85, with a market cap of Rs 13,915 crore.

Concord Biotech Share Price has experienced a notable rise today, increasing by 6.05% to reach Rs 1,413.85. This price movement has elevated the company's market capitalisation to Rs 13,915 crore, positioning it as a significant player in the mid cap category. The stock opened at Rs 1,321.35 and reached a high of Rs 1,420.85, reflecting strong investor interest. The day's trading volume was substantial, with a total of 472,555 shares exchanged across BSE and NSE.

< While the data confirms the price event, it does not establish a specific catalyst for this movement. Investors and analysts will be keen to explore the technical and fundamental aspects that may have contributed to this performance.

Concord Biotech Ltd. (CONCORDBIO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,413.85
Previous Close	Rs 1,333.2
Today's Change	+Rs 80.65 (+6.05%)
Day Open	Rs 1,321.35
Day High	Rs 1,420.85
Day Low	Rs 1,321.35
Current Volume (BSE)	28,856
BSE Traded Volume	28,856
NSE Traded Volume	4,43,699
Combined NSE + BSE Volume	4,72,555
Turnover	Rs 4.08 crore
Market Capitalisation	Rs 13,915 crore
Market Cap Category	Mid Cap

Concord Biotech Ltd. (CONCORDBIO) traded at Rs 1,413.85. versus the previous close of Rs 1,333.2, a rise of 6.05%. The stock opened at Rs 1,321.35, reached Rs 1,420.85, touched Rs 1,321.35. Reported volume was 28,856.

Concord Biotech Ltd. (CONCORDBIO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 13,915 crore

The healthcare sector, with a benchmark P/E median of 25.77 and an average of 94.79, sets a context for evaluating Concord Biotech's performance. The sector's P/B median is 1.93, with an average of 2.53, offering a benchmark for comparison. Concord Biotech's financial metrics, such as ROE and ROCE, are essential for assessing its profitability and efficiency, although specific figures are not available in the data.

Investors will be interested in Concord Biotech's growth prospects and financial health, especially in comparison to its peers. The company's ability to generate returns and manage its capital effectively will be key factors in sustaining investor interest.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	25.77x
Benchmark Average P/E	94.79x
Benchmark P/E Range	3.3x to 3,417.8x
Benchmark Median P/B	1.93x
Benchmark Median ROE	10.74%
Benchmark Median ROCE	13.24%
Company Market Capitalisation	Rs 13,915 crore
Benchmark Median Market Cap	Rs 140.91 crore

Concord Biotech Ltd. (CONCORDBIO) is classified under sector: Healthcare.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

The healthcare sector, encompassing 198 companies, provides a broad benchmark for evaluating Concord Biotech's performance. With a sector P/E median of 25.77 and an average of 94.79, the industry presents a diverse range of valuations. Concord Biotech's market capitalisation of Rs 13,915 crore places it above the sector median of Rs 140.91 crore, highlighting its significant market presence.

The sector's P/B median of 1.93 and average of 2.53 offer a context for assessing Concord Biotech's valuation. The company's ROE and ROCE metrics, although not specified, are critical for understanding its profitability relative to the sector's median ROE of 10.74% and ROCE of 13.24%. These benchmarks provide a framework for evaluating Concord Biotech's financial performance and market positioning.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,950.66	0	0.75	-2.89	-0.26
Hikal Ltd.	HIKAL	2,726.18	0	2.23	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,700.98	39.17	7.93	28.21	26.35
Panacea Biotec Ltd.	PANACEABIO	2,598.26	0	8.89	0	5.36
Beta Drugs Ltd.	BETA	2,475.7	58.88	9.32	18.65	22.17

Concord Biotech Ltd. (CONCORDBIO) has a market capitalisation of Rs 13,915 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

In the healthcare sector, Concord Biotech competes with several peers, including Dishman Carbogen Amcis Ltd., Hikal Ltd., and Kwality Pharmaceuticals Ltd. These companies offer a range of market capitalisations and financial metrics, providing a comparative backdrop for Concord Biotech's performance.

Dishman Carbogen Amcis Ltd. has a market cap of Rs 2,950.66 crore, with a P/B ratio of 0.75 and negative ROE and ROCE. Hikal Ltd. presents a market cap of Rs 2,726.18 crore, with a P/B of 2.23, ROE of 15.22%, and ROCE of 16.15%. Kwality Pharmaceuticals Ltd. stands out with a P/E of 39.17, P/B of 7.93, and ROE of 28.21%, highlighting its strong financial performance.

Concord Biotech's market cap of Rs 13,915 crore positions it well above these peers, indicating its substantial market presence. The comparison of financial metrics, such as P/E, P/B, ROE, and ROCE, provides insights into Concord Biotech's relative strengths and areas for improvement.

Why Investors Are Watching Concord Biotech

Concord Biotech's recent price rise has captured the attention of investors and analysts. The company's strong market presence and performance in the healthcare sector make it a stock to watch.

• Price Action: A 6.05% rise today, surpassing the mid cap threshold.
• Technical Position: Strong upward momentum observed.
• Fundamental Context: Significant market cap in the healthcare sector.
• Sector Positioning: Above median market cap, indicating strong presence.

Investors should monitor Concord Biotech's financial performance, market trends, and sector developments to understand its future trajectory. The company's ability to sustain growth and profitability will be key factors in maintaining investor interest.

About Concord Biotech

Concord Biotech Ltd. operates within the healthcare sector, focusing on the development and manufacturing of biopharmaceutical products. The company is involved in various segments, including pharmaceuticals and drugs, contributing to its substantial market presence. Concord Biotech's operations are aligned with industry standards, ensuring high-quality product offerings.

The company's revenue mix and product portfolio are designed to cater to diverse market needs, positioning it as a competitive player in the healthcare industry. Concord Biotech's commitment to innovation and quality has enabled it to maintain a strong foothold in the market, attracting interest from investors and stakeholders alike.

Track Concord Biotech Share Price on Univest

Use Concord Biotech Ltd. (CONCORDBIO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track Concord Biotech Share Price on Univest for real-time updates and insights. Univest provides comprehensive data, including live share prices, technical indicators, fundamental ratios, and shareholding patterns. Users can also access 52-week levels and market insights to make informed investment decisions.

Frequently Asked Questions

What is Concord Biotech's current share price?

Ans. Concord Biotech's current share price is Rs 1,413.85, reflecting a 6.05% increase from the previous close of Rs 1,333.20. The stock moved 6.05% during the session. The intraday range extended from Rs 1,321.35 to Rs 1,420.85.

How much did Concord Biotech's share price rise today?

Ans. Concord Biotech's share price rose by 6.05% today, marking a significant gain in the mid cap category. The stock moved 6.05% during the session. The intraday range extended from Rs 1,321.35 to Rs 1,420.85.

How does Concord Biotech's market cap compare to its peers?

Ans. Concord Biotech's market cap of Rs 13,915 crore is substantially higher than its peers, indicating a strong market presence. The company operates in the Healthcare sector. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals Ltd.

What is the sector P/E median for healthcare?

Ans. The sector P/E median for healthcare is 25.77, providing a benchmark for evaluating Concord Biotech's valuation. The relevant peer median P/E is 25.77x. The peer average P/E is 94.79x. The stock belongs to the Healthcare sector.

Who are Concord Biotech's main competitors?

Ans. Concord Biotech's main competitors include Dishman Carbogen Amcis Ltd., Hikal Ltd., and Kwality Pharmaceuticals Ltd., among others. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals Ltd.